Back to Technologies Available for Partnering

Fam3PRO: A Leap Forward in Cancer Risk Prediction  

  • Diagnostics

Project Overview

  • As genetic testing becomes more comprehensive and accessible, there is a growing need for tools that integrate family history, genetic data, and the latest research to provide accurate, multi-syndrome cancer risk predictions.   
  • Scientists at Dana-Farber have developed Fam3PRO, a next-generation cancer risk prediction tool that offers a robust, data-driven framework for identifying individuals at high risk of hereditary cancers.   
  • Fam3PRO provides a comprehensive and user-friendly approach to understanding hereditary cancer risk  
  • Dana-Farber is actively seeking partners to collaborate on the further development and dissemination of Fam3PRO, including user interfaces and integration with advanced AI technologies like natural language processing.  

Early cancer identification of individuals at high risk is critical for prevention and treatment. Genetic testing has revolutionized cancer risk assessment, but its cost and complexity have historically limited its accessibility. In the 1990s, researchers like Giovanni Parmigiani, PhD, professor of Biostatistics at Harvard TH Chan School of Public Health and Dana-Farber Cancer Institute, began developing statistical models to identify individuals at high risk of carrying genetic mutations, such as BRCA1 and BRCA2, which are associated with increased risks of breast, ovarian, and other cancers. These models were essential when genetic testing was prohibitively expensive and less comprehensive.  

Today, genetic testing panels can screen for mutations in multiple genes; however, interpreting the results and integrating them with family history remains a significant challenge. Tools like Fam3PRO address this gap by providing clinicians and researchers with a robust, data-driven framework for predicting cancer risk and guiding personalized interventions.  

Technology

Fam3PRO is the latest innovation in cancer risk prediction, building on decades of research and development in statistical modeling and genetic epidemiology. This next-generation tool is the successor to PanelPRO, a widely recognized multi-syndrome cancer risk prediction model developed by Parmigiani and senior statistical research scientist Danielle Braun, PhD in the BayesMendel Lab at Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health. Fam3PRO represents a significant evolution in both scope and functionality, offering clinicians and researchers a more comprehensive and user-friendly approach to understanding hereditary cancer risk.  

PanelPRO was introduced as a groundbreaking tool for multi-syndrome cancer risk prediction, addressing the limitations of earlier single-syndrome models like the  BayesMendelTM risk prediction models. While tools such as  BayesMendelTM focused on specific hereditary cancer syndromes—like BRCA1/2 mutations linked to breast and ovarian cancer—PanelPRO expanded the scope to include multiple syndromes and genes. It integrated family history data with genetic testing results to predict the likelihood of carrying mutations in 24 genes and the risk of developing up to 18 types of cancer. This made PanelPRO one of the first tools capable of providing a holistic view of hereditary cancer risk across a wide range of conditions.  

PanelPRO was implemented as an R statistical package, making it accessible to researchers and clinicians with expertise in data analysis. However, it lacked a user-friendly interface, requiring users to work directly with raw data files and statistical programming. While this approach was effective for research purposes, it limited the tool’s accessibility for broader clinical use, particularly for genetic counselors and healthcare providers who interact directly with patients.  

Recognizing the need for a more versatile and accessible tool, the BayesMendel Lab embarked on the development of Fam3PRO. Officially renamed from PanelPRO in November 2024, Fam3PRO retains the robust statistical foundation of its predecessor while introducing key enhancements that address the evolving needs of clinicians, researchers, and patients.  

Fam3PRO builds on PanelPRO’s multi-syndrome framework but incorporates several advancements:  

  • Expanded Scope: Fam3PRO continues to predict the probability of carrying mutations in 24 genes and assesses the risk of developing up to 18 types of cancer. However, it integrates updated genetic associations and risk factors, reflecting the latest scientific discoveries in hereditary cancer syndromes.  
  • Improved Usability: While PanelPRO was primarily an R statistical package, Fam3PRO is being developed with plans for user-friendly interfaces. These interfaces aim to make the tool accessible to genetic counselors, clinicians, and even patients, enabling real-time risk assessment and decision-making.  
  • AI Integration: Fam3PRO incorporates emerging AI technologies, such as natural language processing, to streamline the integration of new scientific literature into its risk models. This ensures that the tool remains up-to-date with the latest research findings, particularly for rare genetic mutations and less-studied cancer syndromes.  

Fam3PRO represents a shift from a purely research-focused tool to a versatile platform that bridges the gap between research and clinical practice. Its name reflects its emphasis on family-based risk prediction (“Fam”), its ability to analyze complex family trees (“Tree”), and its professional-grade capabilities (“Pro”). This evolution underscores the tool’s commitment to empowering healthcare providers and patients with actionable insights into hereditary cancer risk.  

Fam3PRO also addresses the challenges of interpreting genetic testing results in the context of family history. For example, while BRCA1/2 mutations are well-known for their association with breast and ovarian cancer, they are also linked to pancreatic cancer, prostate cancer, and melanoma. Fam3PRO accounts for these broader associations, as well as the risks associated with other genes, providing a comprehensive risk profile for each individual.  

Fam3PRO is more than just a tool—it is a platform for advancing personalized medicine. By combining cutting-edge statistical modeling with emerging AI technologies, Fam3PRO is poised to transform the way hereditary cancer risk is assessed and managed. Its evolution from PanelPRO reflects a commitment to innovation, accessibility, and patient-centered care, ensuring that the tool remains at the forefront of cancer risk prediction for years to come.  

Further Information:  

Team Members: Giovanni Parmigiani, PhD, Danielle Braun, PhD, Jane Liang, MD, Theodore Huang, PhD

Applications

Fam3PRO has a wide range of applications in both clinical and research settings:  

  • Genetic Counseling: Fam3PRO helps genetic counselors assess the likelihood of hereditary cancer syndromes and guide patients on genetic testing and preventive measures.  
  • Cancer Screening: By identifying individuals at high risk, the tool supports personalized screening strategies, such as earlier or more frequent colonoscopies for Lynch syndrome carriers.  
  • Research: Fam3PRO is available for academic research, enabling studies on cancer risk prediction, genetic epidemiology, and the development of new interventions.  
  • Patient Tools: While Fam3PRO itself is a statistical package, efforts are underway to develop user-friendly interfaces for clinicians and patients. For example, the MyLynch app, developed by the same team, provides personalized risk estimates and prevention strategies for individuals with Lynch syndrome.  

Plans are in place to create clinician- and patient-facing interfaces to make Fam3PRO more accessible. Future versions may incorporate advanced AI techniques, such as natural language processing, to integrate findings from the latest scientific literature. The tool’s framework could be adapted for other hereditary conditions or integrated into broader precision medicine initiatives.  

Opportunities

Fam3PRO is available for non-exclusive licensing, making it accessible to a wide range of organizations, including clinical genetic testing companies, research institutions, and healthcare providers.    

Dana-Farber’s Innovations Office is actively seeking partners to collaborate on the further development and dissemination of Fam3PRO.  

Get in touch

Team Members